Turning scientific promise into meaningful innovation
Turning scientific promise into meaningful innovation
Turning scientific promise into meaningful innovation Making the difference for underserved neurological and rare disease
Insights and points of view from Acadians on our mission and partnerships, business and initiatives, and the communities we serve.
Turning scientific promise into meaningful innovation
Turning scientific promise into meaningful innovation Making the difference for underserved neurological and rare disease
Gutters
(none)
--gutter-safe --gutter-padded --gutter-wide --gutter-content --gutter-narrow Midnight Heading H2
Midnight Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Blue-spruce Heading H2
Blue-spruce Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Turquoise-80 Heading H2
Turquoise-80 Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Glacier Heading H2
Glacier Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Turquoise-10 Heading H2
Turquoise-10 Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
White Heading H2
White Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Grays-10 Heading H2
Grays-10 Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Marigold Heading H2
Marigold Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Carrot Heading H2
Carrot Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Tangerine Heading H2
Tangerine Subheading H3
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Blocks: Aligned to --gutter-content
For more than three decades, Acadia has been at the forefront of healthcare, elevating lives by providing essential solutions to those who need them most. We pioneered the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. Currently, our clinical-stage developments focus on addressing Prader-Willi syndrome, Alzheimer’s disease psychosis, and neuropsychiatric symptoms in CNS disorders.
Life at Acadia
We know that a sound internal environment is what drives innovation. With our leadership as the example of Acadian passion and dedication, we are constantly working to become more sustainable, ethical and inclusive.
- Policy: We have policies that uphold the standards provided by the FDA to ensure quality, safe medicines.
- Management: We take a proactive approach to ensure quality by prioritizing regulatory compliance and performing routine compliance checks.
- Drug Safety: We have a system of robust processes to review and evaluate the safety of our medicines, and we are committed to continuous improvement.
Blocks: Aligned to --gutter-narrow
For more than three decades, Acadia has been at the forefront of healthcare, elevating lives by providing essential solutions to those who need them most. We pioneered the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. Currently, our clinical-stage developments focus on addressing Prader-Willi syndrome, Alzheimer’s disease psychosis, and neuropsychiatric symptoms in CNS disorders.
Ensuring Drug Safety and Quality
Our patients trust us to deliver products that are both safe and effective. We’re creating and refining infrastructures with the help of a dedicated team to manufacture innovative medicines.
)
June 3, 2026 - Employee Spotlight
Regular Card with “Learn More” Inline Link
Patients with Parkinson’s disease may experience hallucinations and/or delusions over the course of their disease.
June 3, 2026 - Employee Spotlight
“Many of us at Acadia have first-hand experience with loved ones impacted by the challenges of the diseases we aim to treat. We are connected by a shared passion to break through these challenges and fight for the lives of the people we serve.”
Steve Davis, President and Chief Executive Officer
Pipeline
NUPLAZID® (pimavanserin) Parkinson’s Disease Psychosis In Market
DAYBUE™ (trofinetide) Rett Syndrome In Market
ACP‑101 Hyperphagia in Prader-Willi Syndrome Phase 3
ACP‑101 Hyperphagia in Prader-Willi Syndrome Phase 3
ACP‑203 Alzheimer’s Disease Psychosis Phase 2
ACP‑203 Alzheimer’s Disease Psychosis Phase 1
ACP‑200 Alzheimer’s Disease Psychosis Preclinical
30 Years of Innovation and Trailblazing
For 30 years, we have delivered on the promise of science to blaze new trails in research and development to deliver new treatment options to help address the unmet need.
2023
FDA Approves DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adults and Pediatric Patients Two Years of Age and Older.
2022
Acadia and Stoke Therapeutics collaborate to pursue multiple RNA-based treatments for severe and rare genetic neurodevelopmental diseases.
Acadia resubmitted supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin), narrowing the proposed indication from dementia-related psychosis to Alzheimer’s disease psychosis. FDA has assigned a Target action date of August 4, 2022, and the FDA’s Division of Psychiatry is planning to hold an Advisory committee meeting on June 17 in connection with its review.‡
2021
New England Journal of Medicine publishes results from the Phase 3 HARMONY study evaluating pimavanserin in patients with dementia-related psychosis.‡
Acadia reports positive top-line results from the Phase 3 Lavender™ study evaluating trofinetide, an investigational drug for the treatment of Rett syndrome.*
2020
Acadia acquires CerSci Therapeutics, adding novel pain program to portfolio.
Acadia and Neuren Pharmaceuticals announce rare pediatric disease designation for trofinetide for the treatment of Rett syndrome.*
Acadia and Vanderbilt University announce an exclusive license agreement and research collaboration to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of central nervous system disorders.
Acadia submits a Supplemental New Drug Application to the U.S. FDA for NUPLAZID® (pimavanserin), for the treatment of hallucinations and delusions associated with dementia-related psychosis.‡ FDA accepts our application.
2019
Acadia initiates Phase 3 CLARITY program with pimavanserin as adjunctive treatment for major depressive disorder.‡
Acadia presents positive top-line results from pivotal Phase 3 HARMONY trial of pimavanserin in patients with dementia-related psychosis‡ at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting.
Acadia announces positive top-line results from Phase 2 ADVANCE trial of pimavanserin as treatment for negative symptoms of schizophrenia.‡
Acadia initiates Phase 3 pivotal study of trofinetide in Rett syndrome*, a rare neurodevelopment CNS disorder.
2018
Acadia reports positive top-line results from Phase 2 CLARITY trial of pimavanserin as adjunctive treatment for major depressive disorder.‡
Acadia signs exclusive North American license agreement for the development and commercialization of trofinetide for Rett syndrome.*
FDA approves new dosing formulation and strength for NUPLAZID® (pimavanserin).
Phase 2 study evaluating pimavanserin in patients Alzheimer’s disease psychosis published in The Lancet Neurology.‡
2017
Acadia is named one of Forbes’ “Most Innovative Growth Companies” (#11 of 100).
2016
FDA Approves NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis.
Acadia reports positive Phase 2 data for pimavanserin in patients with Alzheimer’s disease psychosis.‡
Acadia initiates ENHANCE Phase 3 trial with pimavanserin as adjunctive treatment for schizophrenia with inadequate response to current antipsychotic treatment.‡
Acadia initiates ADVANCE Phase 2 trial with pimavanserin as adjunctive treatment for negative symptoms of schizophrenia.‡
Acadia is added to Large-Cap Russell 1000 Index.
2015
New Drug Application (NDA) for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis Accepted and Granted Priority Review by the FDA.
Steve Davis is appointed as President and Chief Executive Officer.
2014
Acadia receives FDA Breakthrough Therapy Designation for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
2013
Acadia announces publication in The Lancet of pivotal Phase 3 Parkinson’s disease psychosis trial with pimavanserin.
Acadia is added to the NASDAQ Biotechnology and the Russell 2000 indices.
Acadia meets with the FDA, then announces an expedited path to a New Drug Application filing with pimavanserin for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Acadia announces presentation of data from Phase 3 trial with pimavanserin for Parkinson’s disease psychosis at the American Academy of Neurology Annual Meeting.
2012
Acadia reports positive Phase 3 data for pimavanserin in patients with Parkinson’s disease psychosis.
2010
Acadia initiates a pivotal Phase 3 efficacy, tolerability and safety study with pimavanserin in patients with Parkinson’s disease psychosis.
Acadia regains full worldwide rights to pimavanserin following the conclusion of its collaboration with Biovail.
2009
Acadia forms collaboration with Biovail to develop and commercialize pimavanserin in North America.
2007
Acadia reports positive Phase 2 data for pimavanserin as a co-therapy for patients with schizophrenia.‡
2006
Acadia reports positive Phase 2 data for pimavanserin in patients with Parkinson’s disease psychosis.
2004
Acadia completes its initial public offering and trades under the symbol “ACAD” on the NASDAQ Stock Market.
2001
Pimavanserin first synthesized.
Pimavanserin is first synthesized by an Acadia chemist working in Acadia’s Copenhagen facility.
1999
Our scientists start a project to discover new non-dopaminergic antipsychotic agents selectively acting as inverse agonists on the 5-HT2A receptor.
1997
Company name changed to Acadia Pharmaceuticals Inc.
Inspired by the power and beauty of Acadia National Park, the company rebrands.
We shift our focus to developing our own portfolio of product candidates.
Our headquarters moves from Winooski, Vermont, to the biotech hub of San Diego, California
Our medicinal chemistry operations are established in Copenhagen, Denmark—supported by Danish investors.
Acadia establishes its first of several drug discovery and development collaborations with Allergan.
1993
Company founded.
Receptor Technologies is founded by Mark Brann, Ph.D., a professor at the University of Vermont.
The company starts by working with major pharmaceutical companies to perform high-throughput screening based on its proprietary functional genomics platform, R-SAT.
Important Disclosures
*The safety and efficacy of the investigational agent(s) listed above have
not been established or approved by the U.S. Food and Drug Administration (FDA).
‡The safety and efficacy of the investigational use of NUPLAZID®
(pimavanserin) have not been established or approved by the FDA. For NUPLAZID’s FDA-approved
indication, please read the full Prescribing Information, including Boxed WARNING.
)
More to Parkinsons with Ryan Reynolds
More to Parkinsons with Ryan Reynolds
General 2024
General 2023
General 2022
General 2021
General 2020
General 2019
General 2018
General 2017
General 2016
General 2015
General 2014
General 2013
General 2022
General 2021
Earnings 2024
General 2024
General 2023
Earnings 2024
General 2024
General 2023
Earnings 2024
General 2024
General 2023
Earnings 2024
24 Results
To report an Adverse Event or Product Complaint please call (844) 422-2342.